You are here: Industry Insights > Janssen

News List

Janssen seeks EU approval for twice-yearly schizophrenia treatment pharmatimes
December 08, 2020
Janssen has submitted a marketing authorisation extension application to the European Medicines Agency (EMA) for paliperidone palmitate six-monthly (PP6M) as a maintenance treatment for adults living with schizophrenia.
Johnson & Johnson announces initiation of rolling submission for its single-dose Janssen COVID-19 vaccine candidate with the European Medicines Agency worldpharmanews
December 07, 2020
Janssen-Cilag International N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has initiated a rolling submission with the European Medicines Agency (EMA) for its investigational single-dose vaccine candidate for the prevention ...
Janssen buys rights to Hemera’s eye disease gene therapy candidate pharmatimes
December 04, 2020
Johnson & Johnson’s pharmaceuticals division Janssen has purchased rights to acquire an investigational gene therapy asset for geographic atrophy from Hemera Biosciences.
EMA initiates rolling review of Janssen’s Covid-19 vaccine candidate pharmaceutical-technology
December 03, 2020
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has initiated a rolling review of Janssen and Cilag International’s Covid-19 vaccine candidate, Ad26.COV2.S.
Janssen's Tremfya approved for active psoriatic arthritis pharmatimes
November 27, 2020
The European Commission has approved Janssen’s Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA).
Janssen begins second Phase III Covid-19 vaccine trial pharmaceutical-technology
November 17, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) has initiated enrolment and dosing of participants in the Phase III ENSEMBLE 2 trial of a two-dose regimen of JNJ-78436735, an investigational vaccine candidate for preventing Covid-19 ...
Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen prnasia
November 10, 2020
Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, announced that it entered into a multi-target drug discovery agreement with Janssen ...
Janssen Submits sNDA for Expanded Use of XARELTO americanpharmaceuticalreview
October 30, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with ...
Janssen’s psoriasis med Tremfya scores long-term safety and efficacy data pharmatimes
October 19, 2020
Janssen has announced new open-label extension data for Tremfya, with the treatment continuing to show high rates of skin clearance through nearly five years in moderate to severe plaque psoriasis.
Janssen presents five year data of STELARA in treatment of Crohn’s Disease expresspharma
October 14, 2020
Over half of the patients with moderately to severely active CD who were randomised to subcutaneous ustekinumab every eight weeks and continued to receive this dosage in the LTE study maintained clinical response and remission through five years of ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page